Epigenetics is the study of how external factors, such as diet, environment and lifestyle, can alter gene expression without changing the underlying genetic code. Epigenetic pathways refer to the range of mechanisms that underlie these modifications and control the expression of genes. Epigenetic pathways are regulated by small chemical tags called epigenetic marks that are added to the DNA. These cues tell the cell which genes should be expressed and which should remain inactive. Epigenetic marks can be added or removed to control gene expression and to influence the developmental processes of the cell. Epigenetic marks can either silence genes or activate them. The best studied form of epigenetic silencing is DNA methylation, in which molecules called methyl groups are attached to DNA. These methyl groups block gene activity, by interfering with the proteins that bind to the gene and control its expression. On the other hand, acetylation of histones – proteins that package and organize DNA – can promote gene expression. When acetyl groups are added to histones, they can interact with the DNA and help activate the gene. Complex interactions between epigenetic marks, proteins, and other molecules in the cell create a unique set of configurations that determine how genes are expressed. Researchers are using cutting-edge technologies to understand how these pathways interact and how they can influence gene expression and development. Ultimately, epigenetic pathways play a critical role in many biological processes, such as ageing, cell differentiation, and disease. By understanding how epigenetic pathways work, scientists are unlocking vital information that can be used to develop treatments for diseases and improve human health.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States